EU Exacts Toll from Underfunded Countries

With the Sixth Framework Programme (FP6), the European Community has focused funding on projects designed to forge lasting research partnerships across Europe and to achieve highly ambitious goals, such as developing novel technologies for proteomics research, and decreasing the Europe-wide burden of allergy and asthma.The European Life Scientist Organization (ELSO) recently launched a petition to lobby for changes, but it's the scientists from the 10 countries that joined the European Union in

Written byMartina Habeck
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

With the Sixth Framework Programme (FP6), the European Community has focused funding on projects designed to forge lasting research partnerships across Europe and to achieve highly ambitious goals, such as developing novel technologies for proteomics research, and decreasing the Europe-wide burden of allergy and asthma.

The European Life Scientist Organization (ELSO) recently launched a petition to lobby for changes, but it's the scientists from the 10 countries that joined the European Union in May, the so-called accession countries, who pay the highest price.

Under the first call of FP6, more than 100,000 European scientists submitted 12,000 research projects. Teams spent months preparing their proposals, attending meetings throughout Europe to coordinate their activities, and eventually handing in hundreds of pages of detailed information to support their applications.

The success rate of scientists from long-time EU countries was 18.5%. Scientists from accession countries achieved a success rate of only 14%, yet these ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies